Keyphrases
Access to Care
16%
Anti-hypertension Drug
16%
Barriers to Access
16%
Cardiologists
16%
Chronic Disease
16%
Class Level
16%
Clinical Practice Guidelines
16%
Combination Therapy
16%
Coverage Policy
33%
Disease Severity
16%
Drug Class
16%
Drug Coverage
50%
Drug Evidence
16%
Endothelin Receptor Antagonist
33%
Fatal Infection
16%
Health Plans
100%
Hypertension Management
100%
Inconsistency
16%
Medical Center
16%
Patient Access
33%
Phosphodiesterase Type 5 Inhibitors
33%
Prescribers
50%
Progressive Disease
16%
Prostacyclin Pathway Agents
33%
Publicly Available
16%
Pulmonary Arterial Hypertension
100%
Pulmonologist
16%
Randomized Controlled Trial
16%
Rare Diseases
16%
Restrictiveness
16%
Soluble Guanylate Cyclase Stimulator
16%
Specialty Drugs
50%
Step Therapy
83%
Therapy Protocols
83%
Treatment Class
16%
U.S. Food
16%
Nursing and Health Professions
Cardiologist
16%
Chronic Disease
16%
Clinical Guideline
16%
Clinical Protocol
16%
Combination Therapy
16%
Disease Severity
16%
Diseases
16%
Endothelin Receptor Antagonist
33%
Food and Drug Administration
16%
Guanylate Cyclase
16%
Guanylate Cyclase Activator
16%
Phosphodiesterase V Inhibitor
33%
Practice Guideline
16%
Prostacyclin
33%
Pulmonary Hypertension
100%
Pulmonologist
16%
Step Therapy
83%
Medicine and Dentistry
Chronic Disease
16%
Clinical Guideline
16%
Combination Therapy
16%
Disease Severity
16%
Diseases
16%
Endothelin Receptor Antagonist
33%
Guanylate Cyclase
16%
Guanylate Cyclase Activator
16%
Phosphodiesterase V Inhibitor
33%
Prostacyclin
33%
Pulmonary Hypertension
100%
Randomized Controlled Trial
16%
Step Therapy
83%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Disease
16%
Combination Therapy
16%
Disease Severity
16%
Diseases
16%
Endothelin Receptor Antagonist
33%
Guanylate Cyclase
16%
Guanylate Cyclase Activator
16%
Phosphodiesterase V Inhibitor
33%
Prostacyclin
33%
Pulmonary Hypertension
100%
Randomized Controlled Trial
16%